News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
45,893 Results
Type
Article (4232)
Company Profile (4)
Press Release (41657)
Multimedia
Podcasts (15)
Webinars (1)
Section
Business (13049)
Career Advice (89)
Deals (2390)
Drug Delivery (10)
Drug Development (6442)
Employer Resources (6)
FDA (1314)
Job Trends (1055)
News (23239)
Policy (2309)
Tag
Academia (126)
Accelerated approval (2)
Adcomms (1)
Allergies (27)
Alliances (3806)
ALS (14)
Alzheimer's disease (57)
Antibody-drug conjugate (ADC) (15)
Approvals (1357)
Artificial intelligence (43)
Autoimmune disease (21)
Automation (2)
Bankruptcy (10)
Best Places to Work (749)
Biosimilars (10)
Biotechnology (1)
Bladder cancer (2)
Brain cancer (7)
Breast cancer (40)
Cancer (329)
Cardiovascular disease (26)
Career advice (70)
CAR-T (12)
CDC (5)
Cell therapy (30)
Cervical cancer (1)
Clinical research (5530)
Collaboration (124)
Compensation (9)
Complete response letters (8)
COVID-19 (349)
CRISPR (6)
C-suite (67)
Cystic fibrosis (8)
Data (505)
Denatured (1)
Depression (4)
Diabetes (49)
Diagnostics (336)
Digital health (3)
Diversity, equity & inclusion (1)
Drug discovery (19)
Drug pricing (18)
Duchenne muscular dystrophy (13)
Earnings (4539)
Editorial (7)
Employer branding (2)
Employer resources (5)
Events (4975)
Executive appointments (78)
FDA (1532)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (1)
Frontotemporal dementia (4)
Funding (118)
Gene editing (15)
Generative AI (3)
Gene therapy (56)
GLP-1 (155)
Government (345)
Grass and pollen (2)
Guidances (49)
Healthcare (903)
Huntington's disease (3)
Immunology and inflammation (59)
Immuno-oncology (5)
Indications (13)
Infectious disease (384)
Inflammatory bowel disease (19)
Inflation Reduction Act (1)
Influenza (18)
Intellectual property (9)
Interviews (12)
IPO (707)
IRA (3)
Job creations (350)
Job search strategy (70)
Labor market (2)
Layoffs (64)
Legal (440)
Liver cancer (5)
Longevity (1)
Lung cancer (51)
Lymphoma (31)
Machine learning (5)
Management (2)
Manufacturing (62)
MASH (35)
Medical device (758)
Medtech (760)
Mergers & acquisitions (1742)
Metabolic disorders (131)
Multiple sclerosis (25)
NASH (4)
Neurodegenerative disease (26)
Neuropsychiatric disorders (5)
Neuroscience (147)
NextGen: Class of 2025 (260)
Non-profit (183)
Obesity (37)
Opinion (32)
Ovarian cancer (7)
Pain (12)
Pancreatic cancer (17)
Parkinson's disease (13)
Patents (19)
Patient recruitment (25)
Peanut (17)
People (4385)
Pharmaceutical (1)
Pharmacy benefit managers (2)
Phase I (1475)
Phase II (2289)
Phase III (2379)
Pipeline (343)
Policy (21)
Postmarket research (258)
Preclinical (574)
Press Release (2)
Prostate cancer (18)
Psychedelics (1)
Radiopharmaceuticals (22)
Rare diseases (65)
Real estate (423)
Recruiting (3)
Regulatory (1899)
Reports (10)
Research institute (140)
Resumes & cover letters (12)
RNA editing (1)
RSV (12)
Schizophrenia (2)
Series A (23)
Series B (22)
Sickle cell disease (5)
Special edition (4)
Spinal muscular atrophy (11)
Startups (297)
Stomach cancer (1)
Supply chain (7)
Tariffs (11)
The Weekly (14)
Vaccines (154)
Venture capital (11)
Weight loss (29)
Women's health (1)
Date
Today (10)
Last 7 days (52)
Last 30 days (161)
Last 365 days (2316)
2025 (2278)
2024 (2364)
2023 (2620)
2022 (5696)
2021 (3863)
2020 (3012)
2019 (2456)
2018 (1940)
2017 (2681)
2016 (2419)
2015 (2801)
2014 (1980)
2013 (1529)
2012 (1622)
2011 (1613)
2010 (1423)
Location
Africa (89)
Arizona (3)
Asia (2346)
Australia (307)
California (467)
Canada (81)
China (91)
Colorado (5)
Connecticut (5)
Delaware (21)
Europe (19281)
Florida (30)
Georgia (12)
Idaho (1)
Illinois (19)
India (5)
Indiana (9)
Japan (17)
Kansas (7)
Louisiana (1)
Maryland (40)
Massachusetts (363)
Michigan (4)
Minnesota (13)
Missouri (1)
Nebraska (1)
Nevada (1)
New Hampshire (4)
New Jersey (96)
New Mexico (1)
New York (275)
North Carolina (30)
Northern California (331)
Ohio (2)
Oregon (2)
Pennsylvania (74)
Rhode Island (1)
South America (106)
South Carolina (7)
Southern California (112)
Tennessee (1)
Texas (117)
United States (1597)
Utah (15)
Virginia (7)
Washington D.C. (2)
Washington State (8)
Wisconsin (1)
45,893 Results for "sanofi france".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Multiple sclerosis
Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application
Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.
December 15, 2025
·
2 min read
·
Annalee Armstrong
Earnings
Sanofi’s Legacy Vaccine Sales Decline As Americans Skip Flu Shots
Sales of Sanofi’s COVID-19 and flu vaccines fell 17% in the third quarter amid declining vaccination rates and pricing pressures in Europe.
October 24, 2025
·
2 min read
·
Annalee Armstrong
Autoimmune disease
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership
Sanofi bought Dren’s DR-0201 program earlier this year for $600 million upfront and is running two Phase I trials in undisclosed inflammatory indications.
December 15, 2025
·
1 min read
·
Annalee Armstrong
Immunology and inflammation
Sanofi’s Anti-OX40 Blocker Falls ‘Well Below Expectations’ in Phase III Eczema Study
Despite hitting its efficacy targets in the Phase III COAST-1 study, Sanofi’s amlitelimab remains “meaningfully inferior” to Dupixent, according to analysts at Leerink Partners.
September 5, 2025
·
2 min read
·
Tristan Manalac
Radiopharmaceuticals
Sanofi Comes for Novartis’ Radiopharma Crown With ‘Clinically Meaningful’ Pancreatic Tumor Data
Sanofi’s Orano Med-partnered radioligand therapy AlphaMedix achieved all primary efficacy endpoints, which included a measure of overall response rate, in the mid-stage ALPHAMEDIX-02 study.
October 8, 2025
·
2 min read
·
Annalee Armstrong
Earnings
Sanofi Confident Tariffs Will Have Limited Impact on Finances in 2025
For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.
July 31, 2025
·
2 min read
·
Nick Paul Taylor
Venture capital
Sanofi Fattens Venture Unit With $625M Infusion for Rare Disease, Neuro Innovation
Sanofi Ventures, which now has $1.4 billion in total assets, will focus its investment efforts on early players working in immunology, rare diseases, neurology and vaccines.
September 24, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Sanofi’s Neuro Push Arrives in Seoul With $1B+ Alzheimer’s Play
The star of the agreement targets a specific type of tau protein, helping to prevent toxic accumulation in the brain while also preserving the function of healthy tau.
December 16, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
December 11, 2025
·
11 min read
Press Releases
Press Release: Sanofi completes acquisition of Vicebio
December 4, 2025
·
4 min read
1 of 4,590
Next
